Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

77 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials.
Orkin C, Molina JM, Cahn P, Lombaard J, Supparatpinyo K, Kumar S, Campbell H, Wan H, Teal V, Jin Xu Z, Asante-Appiah E, Sklar P, Teppler H, Lahoulou R; DRIVE-FORWARD and DRIVE-AHEAD collaborators. Orkin C, et al. Among authors: teppler h. Lancet HIV. 2024 Feb;11(2):e75-e85. doi: 10.1016/S2352-3018(23)00258-8. Epub 2023 Dec 20. Lancet HIV. 2024. PMID: 38141637 Clinical Trial.
Efficacy, Safety, and Tolerability of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination Tablets in Adolescents Living With HIV: Results Through Week 96 from IMPAACT 2014.
Rungmaitree S, Aurpibul L, Best BM, Li X, Warshaw MG, Wan H, Tobin NH, Jumes P, Leavitt R, McCarthy K, Scheckter R, Ounchanum P, Violari A, Teppler H, Campbell H, Krotje C, Townley E, Moye J, Melvin AJ; IMPAACT 2014 study team. Rungmaitree S, et al. Among authors: teppler h. J Pediatric Infect Dis Soc. 2023 Dec 16;12(12):602-609. doi: 10.1093/jpids/piad078. J Pediatric Infect Dis Soc. 2023. PMID: 37815035 Clinical Trial.
Pharmacokinetics, Tolerability, and Safety of Doravirine and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination Tablets in Adolescents Living With HIV: Week 24 Results From IMPAACT 2014.
Melvin AJ, Yee KL, Gray KP, Yedla M, Wan H, Tobin NH, Teppler H, Campbell H, McCarthy K, Scheckter R, Aurpibul L, Ounchanum P, Rungmaitree S, Cassim H, McFarland E, Flynn P, Cooper E, Krotje C, Townley E, Moye J, Best BM; IMPAACT 2014 study team. Melvin AJ, et al. Among authors: teppler h. J Acquir Immune Defic Syndr. 2023 Feb 1;92(2):153-161. doi: 10.1097/QAI.0000000000003116. J Acquir Immune Defic Syndr. 2023. PMID: 36215957 Free PMC article.
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naive Adults With Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferiority Trial.
Orkin C, Squires KE, Molina JM, Sax PE, Sussmann O, Lin G, Kumar S, Hanna GJ, Hwang C, Martin E, Teppler H. Orkin C, et al. Among authors: teppler h. Clin Infect Dis. 2021 Jul 1;73(1):33-42. doi: 10.1093/cid/ciaa822. Clin Infect Dis. 2021. PMID: 33336698 Free PMC article. Clinical Trial.
Impact of Low Birth Weight and Prematurity on Neonatal Raltegravir Pharmacokinetics: Impaact P1097.
Clarke DF, Lommerse J, Acosta EP, Cababasay MP, Wang J, Spector SA, Chain A, Smith E, Teppler H, Hazra R, Calabrese K, Graham B, Popson S, Bryson Y, Mirochnick M; International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1097 Study Team. Clarke DF, et al. Among authors: teppler h. J Acquir Immune Defic Syndr. 2020 Dec 15;85(5):626-634. doi: 10.1097/QAI.0000000000002492. J Acquir Immune Defic Syndr. 2020. PMID: 32925360 Free PMC article.
Pharmacokinetics and Safety of a Raltegravir-Containing Regimen in Children Aged 4 Weeks to 2 Years Living With Human Immunodeficiency Virus and Receiving Rifampin for Tuberculosis.
Krogstad P, Samson P, Acosta EP, Moye J, Townley E, Bradford S, Brown E, Denson K, Graham B, Hovind L, Sise T, Teppler H, Mathiba SR, Fairlie L, Winckler JL, Slade G, Meyers T; International Maternal Pediatric Adolescent AIDS Clinical Trials Network P1101 Team. Krogstad P, et al. Among authors: teppler h. J Pediatric Infect Dis Soc. 2021 Mar 26;10(2):201-204. doi: 10.1093/jpids/piaa039. J Pediatric Infect Dis Soc. 2021. PMID: 32448902 Free PMC article. Clinical Trial.
Raltegravir (RAL) in Neonates: Dosing, Pharmacokinetics (PK), and Safety in HIV-1-Exposed Neonates at Risk of Infection (IMPAACT P1110).
Clarke DF, Acosta EP, Cababasay M, Wang J, Chain A, Teppler H, Popson S, Graham B, Smith B, Hazra R, Calabrese K, Bryson Y, Spector SA, Lommerse J, Mirochnick M; IMPAACT P1110 Protocol Team. Clarke DF, et al. Among authors: teppler h. J Acquir Immune Defic Syndr. 2020 May 1;84(1):70-77. doi: 10.1097/QAI.0000000000002294. J Acquir Immune Defic Syndr. 2020. PMID: 31913995 Free PMC article. Clinical Trial.
77 results